FORMOSA PHARMACEUTICALS, INC.

FORMOSA PHARMACEUTICALS, INC. is a factory.

Company Introduction:

FORMOSA PHARMACEUTICALS, INC. is a clinical-stage pharmaceutical company based in Taiwan, dedicated to the research, development, and commercialization of innovative new therapies. The company primarily focuses on developing specialty pharmaceuticals, particularly in the ophthalmic sector, but also has programs in oncology and other therapeutic areas. They leverage proprietary technologies, such as their Active Pharmaceutical Ingredient Nanoparticle Technology (APNT) platform, to enhance drug delivery and efficacy.

Formosa Pharmaceuticals maintains its own manufacturing capabilities for both active pharmaceutical ingredients (APIs) and finished drug products. This integrated approach, encompassing research, development, and manufacturing, firmly establishes it as a factory and an R&D-driven entity rather than solely a trading company. Their mission is to improve patient care through novel drug formulations and therapeutic solutions.

Formosa Pharmaceuticals, Inc. Product Portfolio:

Approve Product:

APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) - Marketed under the brand name OTX-1001 in some regions or simply APP13007, indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Pipeline Products:

APP13007 (Additional indications under development)

TSR-011 (Targeting oncology indications)

FPI-001 (Targeting oncology indications)

Note: The company primarily focuses on the development of ophthalmic drugs and oncology therapeutics using its proprietary APNT nanoparticle formulation platform.